Published research on LL-37: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of tissue repair research.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 1 recruiting, 0 active not recruiting, 12 completed.
Number of PubMed records mentioning LL-37, 2016 to 2026 (2026 is year to date).
Most recently started of 20 ClinicalTrials.gov entries.
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus FluidNCT07280754 · Not Yet Recruiting · started 2025-12-30Cathelicidin LL-37 Relation to Potentially Malignant LesionsNCT06219330 · Completed · started 2023-07-01Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in ChildrenNCT05054361 · Recruiting · started 2022-01-01Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva LevelsNCT04946617 · Unknown · started 2021-07-20The Role of Anti-inflammatory Cytokines and Antimicrobial Peptide LL-37 Biomarkers in the Treatment of Periodontal Disease.NCT04404335 · Completed · started 2021-05-17Peri-implant Vitamin D and Cathelicidin (LL-37) LevelsNCT06867250 · Completed · started 2021-04-01Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV PeriodontitisNCT04861493 · Completed · started 2021-02-23Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot UlcersNCT04098562 · Unknown · Phase 2 · started 2019-10Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIVNCT03270709 · Terminated · Phase 1 · started 2018-04-11Salivary TAS, TOS, LL-37 and Dental Status in Passive Smoking ChildrenNCT04292548 · Completed · started 2016-11-16Passive Smoking and LL-37 in ChildrenNCT03639376 · Completed · started 2016-11Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.NCT02806414 · Completed · Phase 1 / Phase 2 · started 2016-07Positive coverage and opinions: this section collects news and commentary that read favorably.
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialEli Lilly and Company (investor.lilly.com) · May 21, 2026Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsEli Lilly and Company (via PR Newswire) · Jun 6, 2026Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CEli Lilly and Company (via PR Newswire) · Jul 23, 2026Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesEli Lilly and Company (via PR Newswire) · Sep 29, 2026Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialEli Lilly and Company (investor.lilly.com) · Dec 11, 2025Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA applicationReuters · Jul 23, 2026Eli Lilly to offer early access to next-gen obesity drug to some patientsReuters · Aug 3, 2026Lilly sets up next-gen obesity war with phase 3 retatrutide dataFierce Biotech · Sep 30, 2026FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsEli Lilly and Company (investor.lilly.com) · Apr 1, 2026Eli Lilly press release archiveEli Lilly and Company · CurrentPrimary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
WITHDRAWN: Corrigendum to "Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the modulation of SIRT3-SOD2-NF-κB signaling pathway" [Int. Immunopharmacol. 129 (2024) 111636].Int Immunopharmacol · 2026 Jul 8 · Feng C et al. · PubMedApoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling.Int J Mol Sci · 2026 Sep 19 · Voronko OE et al. · PubMedAssessing the Safety and Probiotic Potential of Bifidobacterium longum subsp. infantis BI45: A Comprehensive Study from Genomic Analysis to Randomized Controlled Clinical Trial in Healthy Adults.Probiotics Antimicrob Proteins · 2026 May 12 · Song S et al. · PubMedPrecision synbiotic intervention with 2'-fucosyllactose and infant-derived Bifidobacterium modulates gut-immune axis and reduces disease risk in toddlers: a randomized controlled trial.Front Nutr · 2026 Jul 30 · Chen K et al. · PubMedLimosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application.Food Chem Toxicol · 2026 Feb 6 · Jin M et al. · PubMedEfficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.J Med Virol · 2023 Aug · Zhao Y et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.